Three research papers exploring MDMA-assisted therapy for PTSD have been retracted by the journal Psychopharmacology. This follows the recent rejection of MDMA for this use by the Food and Drug Administration (FDA).
The retracted studies, written by researchers affiliated with Lykos Therapeutics, the company behind the rejected treatment application, were found to involve unethical conduct at one of the research sites. Lykos, however, maintains that the retracted research was not part of their submission to the FDA.
This development adds another layer of complexity to the ongoing debate over MDMA-assisted therapy. While some research suggests its potential in treating PTSD, ethical concerns and regulatory hurdles persist. The recent retraction raises questions about the research methodology used and casts a shadow over the overall data supporting MDMA for this purpose.
The FDA’s rejection of MDMA therapy last week cited insufficient evidence of its long-term safety and effectiveness. This, combined with the retracted studies, creates a significant setback for the field. Further research conducted with rigorous ethical standards will be needed before MDMA can be considered a viable treatment option for PTSD.